C9047: Injection, caplacizumab-yhdp, 1 mg
C9047 is a HCPCS Level II code for injection, caplacizumab-yhdp, 1 mg. It belongs to the Outpatient Prospective Payment System section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
Medically Unlikely Edits: units per day
The most units of C9047 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.
- practitioner
- 22 units MAI 3: Date of Service Edit: Clinical · Prescribing Information
- outpatient
- 22 units MAI 3: Date of Service Edit: Clinical · Prescribing Information
The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute, no documentation overrides it. CMS MUE 2026Q4.
The CMS record for C9047
- Long descriptor
- Injection, caplacizumab-yhdp, 1 mg
- Short descriptor
- Injection, caplacizumab-yhdp
- Added
- July 1, 2019
- BETOS
- O1E
- Pricing indicator
- 53: Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Statute.
Codes adjacent to C9047
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If C9047 is not quite right, the correct code is very often within a few positions of it.
- C9039Injection, plazomicin, 5 mgterminated
- C9040Injection, fremanezumab-vfrm, 1mgterminated
- C9041Injection, coagulation factor xa (recombinant), inactivated (andexxa), 10 mgterminated
- C9042Injection, bendamustine hcl (belrapzo), 1 mgterminated
- C9043Injection, levoleucovorin, 1 mgterminated
- C9044Injection, cemiplimab-rwlc, 1 mgterminated
- C9045Injection, moxetumomab pasudotox-tdfk, 0.01 mgterminated
- C9046Cocaine hydrochloride nasal solution (goprelto), 1 mgterminated
- C9048Dexamethasone, lacrimal ophthalmic insert, 0.1 mgterminated
- C9049Injection, tagraxofusp-erzs, 10 mcgterminated
- C9050Injection, emapalumab-lzsg, 1 mgterminated
- C9051Injection, omadacycline, 1 mgterminated
- C9052Injection, ravulizumab-cwvz, 10 mgterminated
- C9053Injection, crizanlizumab-tmca, 1 mgterminated
- C9054Injection, lefamulin (xenleta), 1 mgterminated
- C9055Injection, brexanolone, 1mgterminated